NCT03205891 2018-01-17
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
Phase 1 Withdrawn
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.